The startup Optimi Health Corp. has been granted permission by the Canadian government to export psychedelic substances to Australia for medicinal purposes. These substances include pills infused with psilocybin, an active component in magic mushrooms, and MDMA, all under the approval of the health department.
The rising demand for magic mushrooms in Ontario and other psychedelic substances is not restricted to Canada. Countries worldwide are taking inspiration from Canada, starting to investigate and authorize the medicinal use of serotogenic compounds.
You can confidently buy psychedelics online in Canada from trustworthy sources to tap into your inherent potential.
[toc]Main Takeaways:
- Optimi Health, a Vancouver-based startup, has received a drug establishment license to export magic mushroom pills to Australia.
- In Australia, licensed psychiatrists are allowed to use magic mushrooms to treat chronic depression.
- The treatment consists of three sessions, each lasting about eight hours, spread over five to eight weeks.
The Rise of Psilocybin Capsules in Canada
Optimi, a Vancouver-based startup, aims to take advantage of its certification to broaden the pharmaceutical market for psychedelic drugs and secure an early market entry.
While seven companies have exported psilocybin, MDMA, or both, it has been solely for clinical trial purposes. A spokesperson from Canada’s health department could not confirm whether these exports were for regular patient use and didn’t disclose the companies involved due to privacy reasons.
This success places Optimi among a limited number of international suppliers, with the current market tending more towards clinical rather than recreational use.
What’s in the Pill?
While Optimi hasn’t disclosed the specific mushroom strain used in the pill, they are known to work with a variety of strains, including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, test, and extract its psychedelic mushrooms. This quaint town, home to approximately 3,000 inhabitants, is situated three hours to the east of Vancouver.
Australia and Psychedelic Mushrooms: A Dynamic Relationship
It’s speculated that 1 in every 5 Australians between the ages of 16 and 85 may suffer from a mental health condition. PTSD (post-traumatic stress disorder) has the potential to impact 11% of Australians at any stage in their life, while anxiety disorders are found in about 17% of the populace.
There’s an extensive array of treatment options for mental health issues, yet not all are effective for everyone. Those who don’t find relief from certain treatments may struggle to find an alternative that works for them, making them more susceptible.
Understanding the Procedure
Australia is at the forefront of employing psilocybin, allowing certified psychiatrists to use this controlled substance in the treatment of PTSD and treatment-resistant depression.
In an unexpected decision in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and mushrooms for therapeutic use. The TGA declared these substances to be safe when used in a medically monitored setting for patients with severe mental disorders.
This shift has been groundbreaking for many mental health professionals and researchers. The administration of these substances will be stringently supervised; it’s not as simple as taking a pill and leaving.
The treatment regimen typically consists of three sessions over a period of five to eight weeks. Each session lasts roughly eight hours, with the therapist staying with the patient throughout the entire duration.
Canada’s Advancements in Psilocybin Research
Canada has risen as a key player in psilocybin research, significantly expanding our understanding of this compound. Health Canada, together with various institutions, is leading the charge in investigating psilocybin’s therapeutic potential for treating diverse mental health disorders.
Research institutions are no longer required to classify these substances as illegal or rely on unauthorized dispensaries or mushroom stores. The government now permits certain institutions to cultivate mushrooms for research pursuits.
The newfound ability to access substances previously deemed harmful enables researchers to deepen their understanding of their potential benefits for numerous individuals.
A Cyclical Trend
The 1950s marked the initial realization of the potential that this field held for addressing mental health issues and substance abuse, including alcoholism. The early pioneers of this research were the English psychiatrist, Humphry Osmond, and Canadian biochemist, Abram Hoffer. Their trailblazing work took place at The Saskatchewan Mental Hospital in Weyburn, which significantly progressed under the leadership of then-premier Tommy Douglas. Douglas empowered the medical community with considerable autonomy to explore their medical hypotheses.
Dr. Osmond and Dr. Hoffer conducted exploratory studies with LSD, mescaline, and peyote as potential alternatives to the harsh treatments of electroshock and lobotomy. The direction of their research took unexpected turns, leading to their recommendation for doctors, nurses, and ancillary staff to experiment with these substances.
Canadian Institutes of Health Research
Through its Institute of Neurosciences, Mental Health and Addiction, the Canadian Institutes of Health Research is backing three clinical trials. These trials aim to investigate the therapeutic effectiveness and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Lead Investigator | Budget for the Project |
| A randomized controlled trial | Psychological distress in end-of-life situations for patients with advanced-stage cancer | University of Toronto | Sarah Hales | $928,643 |
| Study on mechanisms supporting psilocybin psychotherapy for treating alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial comparing single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will foster a broader understanding of the benefits derived from controlled substances. The Government of Canada’s Canadian Drugs and Substances Strategy (CDSS) initiative has made this financial support possible.
Further Psychedelic Research
Vancouver psychiatrists have instigated a phase III clinical trial of MDMA, also widely known as ecstasy, for treating post-traumatic stress disorder (PTSD). The regimen includes three eight-hour sessions with MDMA, spaced one month apart, and nine 90-minute sessions without the drug. Researchers consider this trial historically significant as it constitutes the first clinical exploration of an illicit
It’s been over four decades since a psychedelic substance was last introduced.
Getting to Know Psilocybin
Psilocybin is a psychedelic compound found naturally in certain types of mushrooms. Once ingested, it transforms into psilocin. Psilocin then activates serotonin 5-HT2a receptors, which are located on the cortical pyramidal cells in the brain, the primary processing sites.
Studies are currently being conducted on the substance to explore its potential benefits in treating depression, anxiety, addiction, and end-of-life distress by encouraging introspection and spiritual enlightenment.
Why is it Potentially Effective for Depression, PTSD, and Other Conditions?
The active ingredient interacts with several areas of the brain, which makes it potentially beneficial for various mental health conditions. Numerous patients in Canada and Australia have already undergone therapy using this substance, and the results are promising. Reported side effects are minor and temporary, such as a brief increase in anxiety or blood pressure.
Impact on Neurobiology
- Activation of Serotonin Receptors: This substance serves as a partial agonist at serotonin receptors, especially the 5-HT2A subtype, which plays a significant role in mood regulation and emotional processing.
- Default Mode Network (DMN) Regulation: Activity in the DMN is decreased, which promotes introspection, enhances emotional adaptability, and reduces rigid thought patterns.
- Stimulation of Prefrontal and Limbic Regions: The substance’s antidepressant effects originate from its influence on the prefrontal and limbic regions of the brain, including the amygdala. Individuals experiencing depression often show reduced responsiveness to emotional stimuli. This substance boosts the response to positive emotional stimuli in the right amygdala, while moderating the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Promotion of Positive Mood States: The substance induces feelings of joy, interconnectedness, and emotional openness during and after its use.
- Enhanced Emotional Processing: The psychedelic experience may allow individuals to address and process deep-seated emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Studies from Johns Hopkins University and Imperial College Studies show that London-based research suggests potential long-term benefits such as improved mental health, increased life satisfaction, and spiritual growth.
What Can You Discover at Your Local Magic Mushroom Retailers?
Wondering how these substances might affect your mental health? Explore various magic mushroom stores to find a product that suits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, sparks creativity, and enhances productivity and concentration |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Boosts wellness and improves overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Encourages clarity, creativity, and focus. Contains a powerful mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy advantages |
International Acceptance of Psilocybin
Canada isn’t the only country supporting the use of magic mushrooms for mental health purposes. Countries like Australia are also embracing these psychedelics to tackle conditions such as depression and PTSD. They are procuring top-quality psychedelic capsules from trusted sources. With proper supervision, patients can significantly improve their quality of life. Strongest Cubensis Strain Canada, a magic mushroom dealer, offers a variety of products, from pills to LSD edibles.
Frequently Asked Questions
How do psilocybin and MDMA compare?
Both psilocybin and MDMA provide therapeutic benefits by enhancing mental health. Psilocybin interacts with serotonin 2A receptors, proving helpful in treating depression and addiction.
Conversely, MDMA promotes empathy and is effective in PTSD treatment. It exhibits potential in boosting emotional processing and
Despite being classified as a controlled substance, it still offers therapeutic outcomes.
Is this treatment option accessible to every Australian?
Not all Australians can access this treatment. In Australia, the suitability of individuals to use the substance is evaluated based on factors such as existing heart conditions and history of psychosis. Only patients who have not found relief with traditional treatments for conditions such as depression, anxiety, or PTSD can avail of this treatment.
What is the impact of Canada’s mushroom exports?
Canada is strategizing to become a leader in the psychedelics market, similar to its position in the cannabis industry. This move could encourage more companies to produce high-quality products. As a result, Canada could become a leader in the hallucinogen market, strengthen its economy, and make treatments more accessible to other countries. This would also discourage other countries from obtaining their hallucinogens from illegal dispensaries or suppliers, ensuring safety.
Articles That Might Interest You:
